Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunotherapy Combinations in Advanced NSCLC With High PD-L1 Expression
NCT06162572Phase 2Active, not recruiting
- Sponsor
- Servier
- Start
- Aug 2024
- Primary completion
- Apr 2027
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Therapeutic Vaccines
- Countries
- 13
01
Overview
A Phase 2 trial of S095018, sym024, sym021 in non-small cell lung cancer (NSCLC), sponsored by Servier. Started Aug 2024; status: active, not recruiting.
02
Drugs
S095018sym024sym021
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06162572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06162572.